(:ICPT)

Feb 29, 2024 08:30 am ET
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the...
Nov 13, 2023 08:00 am ET
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg...
Nov 10, 2023 08:00 am ET
Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023
Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly-owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced new data...
Nov 08, 2023 09:13 am ET
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the...
Oct 24, 2023 03:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTA, SPLK, ICPT, FNCB
NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 23, 2023 08:55 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger - ORTX, SRT, CHS, ICPT
NEW YORK, Oct. 23, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2023 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Oct 21, 2023 09:28 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, MRTX, ICPT
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SP® Plus Corporation (NASDAQ: SP)’s...
Oct 20, 2023 02:37 pm ET
Moore Kuehn Encourages ICPT, SRT, PCTI, and SP Investors to Contact Law Firm
NEW YORK, Oct. 20, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Oct 18, 2023 09:50 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMTI, ICPT, FNCB
NEW YORK, Oct. 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 18, 2023 05:35 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CHS, ICPT, ORTX, SRT
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2023 ISS Securities Class Action Services Report and...
Oct 16, 2023 03:27 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, SCU, ICPT
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: American Equity Investment Life...
Oct 16, 2023 12:53 pm ET
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, I
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intercept Pharmaceuticals, Inc. (NasdaqGS: ICPT) to Alfasigma S.p.A. Under the terms of the proposed transaction, shareholders of Intercept will receive $19.00 in cash for each share of Intercept that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 10, 2023 12:47 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMTI, CHS, FNCB, ICPT
NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 09, 2023 07:07 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - SATS, ICPT, AMNB, CHS
NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2023 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Oct 08, 2023 10:25 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICPT, FNCB, PFIS
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Intercept Pharmaceuticals, Inc....
Oct 04, 2023 05:36 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPLK, ICPT, CHS, AMTI
NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 04, 2023 01:52 pm ET
Moore Kuehn Encourages AMTI, SPLK, ICPT, and CHS Investors to Contact Law Firm
NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Oct 03, 2023 12:33 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICPT, PNT
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Intercept Pharmaceuticals, Inc....
Oct 03, 2023 11:54 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc.
BALA CYNWYD, October 3, 2023 /Globe Newswire/ -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman...
Sep 30, 2023 07:00 pm ET
Lifshitz Law PLLC Announces Investigations of APRN, RENB, ICPT
Renovaro Biosciences, Inc. (NASDAQ: RENB) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of RENB and GEDi Cube Intl Ltd. Under the terms of the proposed transaction, GEDi Cube...
Sep 27, 2023 09:55 pm ET
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, I
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intercept Pharmaceuticals, Inc. (NasdaqGS: ICPT) to Alfasigma S.p.A. Under the terms of the proposed transaction, shareholders of Intercept will receive $19.00 in cash for each share of Intercept that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Sep 27, 2023 08:35 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – ICPT, SPLK, RPT, PFSW
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2023 ISS Securities Class Action Services Report and headquartered...
Sep 27, 2023 12:45 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ:ICPT) for violations of the securities laws.
Sep 27, 2023 07:42 am ET
ICPT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) to Alfasigma S.p.A. for $19.00 per share in cash is fair to Intercept shareholders. Halper Sadeh encourages...
Sep 26, 2023 03:25 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICPT, PFSW, AVTA, CATC
NEW YORK, Sept. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sep 26, 2023 01:22 pm ET
Shareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigma
MILWAUKEE, Sept. 26, 2023 /PRNewswire/ -- Ademi LLP is investigating Intercept (Nasdaq: ICPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Alfasigma.
Sep 26, 2023 11:27 am ET
ICPT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Intercept Pharmaceuticals to Alfasigma
The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”) to Alfasigma for $19.00 per share in cash. If you remain an Intercept shareholder and have...
Sep 26, 2023 10:54 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc.
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Sep 26, 2023 09:00 am ET
ICPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) to Alfasigma S.p.A. for $19.00 per share in cash is fair to Intercept shareholders.
Sep 26, 2023 08:00 am ET
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT, “Intercept”), a leading biopharmaceutical company in rare and serious liver diseases, today announced that they have...
Sep 05, 2023 08:30 am ET
Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that Jerry Durso, President and Chief...
Aug 02, 2023 07:00 am ET
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced its financial results for the quarter ended...
Jul 26, 2023 08:00 am ET
Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on...
Jul 17, 2023 06:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ:ICPT) for violations of the securities laws.
Jul 13, 2023 09:31 am ET
Thinking about buying stock in Palo Alto Networks, C3.ai, Camtek, Intercept Pharmaceuticals, or Sea?
NEW YORK, July 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PANW, AI, CAMT, ICPT, and SE .
Jun 23, 2023 09:31 am ET
Thinking about buying stock in SoundHound AI, Virios Therapeutics, Locafy, Intercept Pharmaceuticals, or D-Wave Quantum?
NEW YORK, June 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOUN, VIRI, LCFY, ICPT, and QBTS.
Jun 23, 2023 06:30 am ET
Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced a restructuring to strengthen the Company’s focus on rare and serious liver diseases and significantly reduce operating expenses, including discontinuing all nonalcoholic...
Jun 23, 2023 02:45 am ET
Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced new results from a planned interim analysis...
Jun 22, 2023 05:45 pm ET
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration...
Jun 22, 2023 07:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSIWRE / June 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ:ICPT) for violations of the securities laws.
Jun 20, 2023 06:00 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ:ICPT) for violations of the securities laws.
Jun 17, 2023 10:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT
Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ: ICPT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529,...
Jun 15, 2023 05:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT
NEW YORK, June 15, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 07, 2023 07:00 am ET
Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced initial results from a planned interim...
May 31, 2023 08:00 am ET
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in...
May 30, 2023 04:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT
NEW YORK, May 30, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
May 28, 2023 08:35 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ: ICPT) for violations of the securities laws.
May 28, 2023 12:47 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT
Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ: ICPT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529,...
May 27, 2023 09:00 pm ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ: ICPT) for violations of the securities laws.
May 26, 2023 09:50 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ:ICPT) for violations of the securities laws.
May 25, 2023 11:35 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ:ICPT) for violations of the securities laws.
May 24, 2023 09:50 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ:ICPT) for violations of the securities laws.
May 22, 2023 10:50 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ:ICPT) for violations of the securities laws.
May 22, 2023 09:00 am ET
Kaplan Fox Investigates Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) securities. Click Here To Join Investigation. If you purchased Intercept...
May 21, 2023 06:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT
Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ: ICPT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
May 19, 2023 06:45 pm ET
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the outcome of the U.S. Food and Drug...
May 19, 2023 04:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT
NEW YORK, May 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
May 19, 2023 07:05 am ET
Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that NASDAQ has halted trading of the...
May 18, 2023 04:15 pm ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ:ICPT) for violations of the securities laws.
May 18, 2023 10:25 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (“Intercept” or “the Company”) (NASDAQ:
May 17, 2023 02:18 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (“Intercept” or “the Company”) (NASDAQ:
May 16, 2023 05:00 pm ET
Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug...
Apr 27, 2023 07:00 am ET
Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
Apr 27, 2023 06:55 am ET
Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that seven abstracts in PBC and NASH...
Apr 13, 2023 08:00 am ET
Intercept to Announce First Quarter 2023 Financial Results and Provide Update on Commercial Launch Strategy for NASH on April 27, 2023   
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2023 financial results...
Mar 10, 2023 09:05 am ET
Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Gastrointestinal Drugs...
Mar 09, 2023 08:00 am ET
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in...
Mar 02, 2023 07:00 am ET
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth...
Feb 27, 2023 08:00 am ET
Intercept Pharmaceuticals to Participate in Cowen’s 43rd Annual Health Care Conference on March 7, 2023 
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Feb 23, 2023 08:00 am ET
Intercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full-year 2022...
Jan 19, 2023 08:00 am ET
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug...
Jan 05, 2023 08:00 am ET
Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Jan 04, 2023 09:00 am ET
Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid...
Dec 23, 2022 07:50 am ET
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has resubmitted a New Drug...
Dec 08, 2022 06:00 pm ET
New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, is pleased to share that The American Journal of...
Nov 22, 2022 08:00 am ET
Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022 
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Nov 07, 2022 06:55 pm ET
Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced plans to focus development of its...
Nov 07, 2022 08:00 am ET
Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional supportive data from its...
Nov 06, 2022 08:00 am ET
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced that results from two analyses assessing the...
Nov 01, 2022 07:00 am ET
Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
Oct 31, 2022 04:05 pm ET
Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced multiple abstracts on obeticholic acid...
Oct 25, 2022 08:00 am ET
Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2022 financial results...
Oct 12, 2022 08:00 am ET
Intercept Pharmaceuticals to Participate in H.C. Wainwright’s 6th Annual NASH Investor Conference on October 17, 2022
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Sep 30, 2022 09:35 am ET
Thinking about buying stock in F45 Training, Edesa Biotech, Amyris, Carnival Corp, or Intercept Pharmaceuticals?
NEW YORK, Sept. 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FXLV, EDSA, AMRS, CCL, and ICPT.
Sep 30, 2022 07:55 am ET
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that REVERSE, a Phase 3 study...
Sep 21, 2022 07:30 am ET
Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced a summary of the actions it has taken...
Sep 20, 2022 12:45 pm ET
Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced a key publication in Gastroenterology...
Sep 07, 2022 08:00 am ET
Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Aug 29, 2022 08:00 am ET
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in...
Aug 19, 2022 07:30 am ET
Intercept Pharmaceuticals Announces Repurchase of Convertible Notes
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered into...
Aug 18, 2022 08:00 am ET
Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the management team of Intercept...
Aug 03, 2022 07:00 am ET
Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
Jul 27, 2022 08:00 am ET
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2022 financial...
Jul 07, 2022 07:30 am ET
Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced positive topline results from a new...
Jul 01, 2022 04:01 pm ET
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept...
Jun 21, 2022 07:30 am ET
Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts highlighting...
Jun 06, 2022 06:30 am ET
Intercept Provides Update on NASH Regulatory Timeline
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced an update on the timing of its pre-submission...
Jun 03, 2022 07:30 am ET
Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced results from two studies designed to evaluate...
May 11, 2022 08:00 am ET
Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the first patient has been dosed in a...
May 06, 2022 09:31 am ET
Thinking about buying stock in TPI Composites, Sema4 Holdings, Highpeak Energy, Intercept Pharmaceuticals, or Tonix Pharmaceuticals?
NEW YORK, May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TPIC, SMFR, HPK, ICPT, and TNXP.
May 06, 2022 07:00 am ET
Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
May 05, 2022 08:30 am ET
Thinking about buying stock in Intercept Pharmaceuticals, Hycroft Mining, Albemarle Corp, Sunrun, or Hudson Technologies?
NEW YORK, May 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ICPT, HYMC, ALB, RUN, and HDSN.
May 05, 2022 07:17 am ET
Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced it has entered into an agreement to...
May 02, 2022 08:00 am ET
Intercept to Announce First Quarter 2022 Financial Results on May 6, 2022
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2022 financial results...
Mar 02, 2022 07:00 am ET
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth...
Feb 23, 2022 08:49 am ET
Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2021...
Jan 11, 2022 07:30 am ET
Thinking about buying stock in Accolade, Vir Biotechnology, bluebird bio, Energy Focus, or Intercept Pharmaceuticals?
NEW YORK, Jan. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACCD, VIR, BLUE, EFOI, and ICPT.
Jan 06, 2022 05:07 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers - ICPT
NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05377, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Intercept securities between September 28, 2019 and October 7, 2020, both dates inclusive (the "Class Period"), seeking to recover damages cau
Dec 20, 2021 08:00 am ET
Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that top-line data from its Phase 3...
Dec 13, 2021 10:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Dec 09, 2021 07:00 am ET
Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has formally notified the...
Nov 15, 2021 08:00 am ET
Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced results from a new analysis examining...
Nov 11, 2021 08:00 am ET
Intercept to Present at Upcoming Investor Conferences
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Nov 03, 2021 09:31 am ET
Thinking about buying stock in PROG Holdings, Criteo SA, Pacific Biosciences, Allena Pharmaceuticals, or Intercept Pharmaceuticals?
NEW YORK, Nov. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRG, CRTO, PACB, ALNA, and ICPT.
Nov 03, 2021 07:00 am ET
Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
Nov 02, 2021 08:00 am ET
Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts on obeticholic...
Oct 27, 2021 08:00 am ET
Intercept to Announce Third Quarter 2021 Financial Results on November 3, 2021
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2021 financial results...
Oct 13, 2021 10:46 am ET
Thinking about buying stock in Globalstar, Ford, Intercept Pharmaceuticals, Workhorse Group, or Norwegian Cruise Line?
NEW YORK, Oct. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GSAT, F, ICPT, WKHS, and NCLH.
Sep 21, 2021 08:00 am ET
Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Sep 13, 2021 08:00 am ET
Intercept Pharmaceuticals Announces Convertible Notes Repurchase
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered into...
Sep 01, 2021 08:00 am ET
Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Aug 10, 2021 09:43 pm ET
Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered into...
Jul 29, 2021 07:00 am ET
Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
Jul 19, 2021 07:00 am ET
Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial results...
Jun 21, 2021 08:00 am ET
Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts regarding the...
Jun 15, 2021 08:00 am ET
Intercept to Present at the Raymond James 2021 Human Health Innovation Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Jun 09, 2021 08:00 am ET
Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey,...
Jun 07, 2021 08:00 am ET
Intercept Appoints Andrew Saik as Chief Financial Officer
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Andrew Saik as Chief...
May 27, 2021 08:00 am ET
Intercept to Present at the Jefferies Virtual Healthcare Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
May 26, 2021 04:30 pm ET
Intercept Announces Updated Ocaliva® (obeticholic acid) U.S. Prescribing Information
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or...
May 12, 2021 08:00 am ET
Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
May 06, 2021 07:00 am ET
Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter...
Apr 26, 2021 08:00 am ET
Intercept to Announce First Quarter 2021 Financial Results on May 6, 2021
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2021 financial results...
Mar 10, 2021 08:00 am ET
Intercept Announces Departure of Chief Financial Officer
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Sandip Kapadia, Chief Financial...
Feb 25, 2021 07:00 am ET
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth...
Feb 23, 2021 08:00 am ET
Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar...
Feb 19, 2021 08:00 am ET
Intercept to Present at Upcoming Investor Conferences
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Feb 17, 2021 08:00 am ET
Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer to Lead the Commercial Launch of Once-Nightly FT218
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced...
Feb 17, 2021 08:00 am ET
Intercept Appoints Linda Richardson as Chief Commercial Officer
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Linda Richardson as...
Feb 11, 2021 08:00 am ET
Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2020...
Jan 27, 2021 01:35 pm ET
Intercept Company Statement on Analyst Note
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that an analyst note commenting on the...
Jan 11, 2021 08:00 am ET
Intercept Appoints Jared M. Freedberg as General Counsel and Secretary
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jared M. Freedberg...
Jan 05, 2021 08:00 am ET
Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief...
Jan 04, 2021 08:47 am ET
ICPT INVESTOR DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Filed Against Intercept Pharmaceuticals, In
NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Intercept Pharmaceuticals Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) from September 28, 2019,  through October 7, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934.
Jan 04, 2021 07:30 am ET
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir
LOS ANGELES, Jan. 4, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ: ICPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Jan 03, 2021 11:00 am ET
ICPT Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Intercept Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 4, 2021
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ: ICPT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Intercept securities between September 28, 2019 and October 7, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Jan 02, 2021 10:19 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ICPT
NEW YORK, Jan. 2, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc.  ("Intercept" or the "Company") (NASDAQ: ICPT) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05377, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Intercept securities between September 28, 2019 and October 7, 2020, both dates inclusive (the "Class Period"), seeking to recover damages ca
Jan 01, 2021 09:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Intercept Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of investors that purchased Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) securities between September 28, 2019 and October 7, 2020 (the “Class Period”). Investors have until January 4, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jan 01, 2021 07:15 pm ET
ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Loss
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”), of the important January 4,...
Dec 31, 2020 12:41 pm ET
ICPT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Filed Against Intercept Pharmaceuticals, In
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Dec 30, 2020 10:00 am ET
ICPT & NVCN Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Dec 30, 2020 10:00 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. (ICPT)
The Law Offices of Frank R. Cruz reminds investors of the upcoming January 4, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:
Dec 28, 2020 09:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Intercept Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of investors that purchased Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) securities between September 28, 2019 and October 7, 2020 (the “Class Period”). Investors have until January 4, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Dec 28, 2020 12:30 pm ET
DEADLINE ALERT for HPQ, ICPT, NVCN, TILE : Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 28, 2020 10:18 am ET
JAN 4 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.– ICPT
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from September 28, 2019 through October 7, 2020, inclusive (the “Class Period”)....
Dec 24, 2020 03:56 pm ET
ROSEN, A TOP RANKED LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action – ICPT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”), of the important January 4,...
Dec 23, 2020 03:00 pm ET
ICPT DEADLINE: Zhang Investor Law Reminds Investors with Losses of the Deadline in Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. – ICPT
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”). To join the class...
Dec 23, 2020 11:00 am ET
ICPT & NVCN Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Dec 22, 2020 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intercept Pharmaceuticals, Neovasc, Interface, and Cabot Oil & Gas and Encourages Investors to Contact
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Neovasc, Inc. (NASDAQ: NVCN),...
Dec 22, 2020 11:47 am ET
ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to
NEW YORK, Dec. 22, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the "Class Period"), of the important January 4, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Intercept investors under the federal securities laws.
Dec 22, 2020 11:30 am ET
DEADLINE ALERT for HPQ, ICPT, and NVCN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 21, 2020 07:35 pm ET
Intercept Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit - Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) investors that acquired shares between September 28, 2019 and October 7, 2020. Investors have until...
Dec 21, 2020 01:54 pm ET
LOOMING DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.– ICPT
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from September 28, 2019 through October 7, 2020, inclusive (the “Class Period”)....
Dec 21, 2020 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. (ICPT)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 4, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Intercept Pharmaceuticals, Inc....
Dec 19, 2020 05:57 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers – ICPT
Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc.  (“Intercept” or the “Company”) (NASDAQ: ICPT) and certain of its officers.   The class action, filed in United States District Court for the...
Dec 18, 2020 11:21 am ET
LOOMING DEADLINE: Zhang Investor Law Reminds Investors with Losses of the Deadline in Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. – ICPT
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”). To join the class...
Dec 17, 2020 11:30 am ET
DEADLINE ALERT for HPQ, ICPT, NVCN, TILE : Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 16, 2020 06:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc, and Interface and Encourages Investors to Contact the Fir
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Raytheon Technologies Corporation (NYSE: RTX), Intercept Pharmaceuticals, Inc....
Dec 15, 2020 11:00 am ET
DEADLINE ALERT for HPQ, ICPT, and NVCN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 15, 2020 10:12 am ET
ICPT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Filed Against Intercept Pharmaceuticals, In
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Dec 14, 2020 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. (ICPT)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 4, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Intercept Pharmaceuticals, Inc....
Dec 12, 2020 11:51 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers – ICPT
Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc.  (“Intercept” or the “Company”) (NASDAQ: ICPT) and certain of its officers.   The class action, filed in United States District Court for the...
Dec 10, 2020 05:27 pm ET
ROSEN, A GLOBAL AND LEADING LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action – ICPT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”), of the important January 4,...
Dec 10, 2020 11:15 am ET
DEADLINE ALERT for HPQ, ICPT, and NVCN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 10, 2020 08:47 am ET
ICPT INVESTOR DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Filed Against Intercept Pharmaceuticals, In
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Intercept Pharmaceuticals Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) from September 28, 2019,  through October 7, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934.
Dec 10, 2020 08:00 am ET
Intercept Pharmaceuticals Announces Leadership Transition
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerome (Jerry) Durso, currently...
Dec 09, 2020 06:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, and Neovasc and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Raytheon Technologies Corporation (NYSE: RTX), Intercept Pharmaceuticals, Inc....
Dec 09, 2020 12:00 pm ET
DEADLINE ALERT for HPQ, ICPT, NVCN, TILE : Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 09, 2020 09:29 am ET
SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.– ICPT
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from September 28, 2019 through October 7, 2020, inclusive (the “Class Period”)....
Dec 08, 2020 02:00 pm ET
ICPT STOCK DEADLINE: Zhang Investor Law Reminds Investors with Losses of the Deadline in Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. – ICPT
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”). To join the class...
Dec 07, 2020 10:46 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the F
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the "Class Period"), of the important January 4, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Intercept investors under the federal securities laws.
Dec 07, 2020 09:12 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers –  ICPT
Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc.  (“Intercept” or the “Company”) (NASDAQ: ICPT) and certain of its officers.   The class action, filed in United States District Court for the...
Dec 05, 2020 04:02 pm ET
ICPT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Filed Against Intercept Pharmaceuticals, In
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Dec 05, 2020 02:45 pm ET
ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”), of the important January 4, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Intercept investors under the federal securities laws.
Dec 04, 2020 11:15 am ET
DEADLINE ALERT for HPQ, ICPT, and NVCN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 03, 2020 07:45 pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Co
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”), of the important January 4,...
Dec 03, 2020 11:30 am ET
DEADLINE ALERT for HPQ, ICPT, NVCN, TILE : Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 03, 2020 09:00 am ET
Notice of Lead Plaintiff Deadline for Shareholders in the Intercept Pharmaceuticals, Inc. Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Eastern District of New York on behalf of purchasers of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) securities between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”). The case is captioned Chauhan v. Intercept Pharmaceuticals, Inc., No. 20-cv-05377, and is assigned to Judge Sandra Feuerstein. The Intercept class action lawsuit charges Intercept and certain of its executives with violations of the Securities Exchange Act of 1934.
Dec 03, 2020 03:05 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ICPT
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc.  ("Intercept" or the "Company") (NASDAQ: ICPT) and certain of its officers.  The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05377, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Intercept securities between September 28, 2019 and October 7, 2020, both dates inclusive (the "Class Period"), seeking to recover damages c
Dec 02, 2020 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Raytheon Technologies Corporation (NYSE: RTX), Intercept Pharmaceuticals, Inc....
Dec 02, 2020 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. (ICPT)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 4, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Intercept Pharmaceuticals, Inc....
Dec 01, 2020 11:00 am ET
ICPT & NVCN Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Nov 30, 2020 10:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intercept Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ICPT
Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc.  (“Intercept” or the “Company”) (NASDAQ: ICPT) and certain of its officers.   The class action, filed in United States District Court for the...
Nov 26, 2020 12:43 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Con
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the “Class Period”), of the important January 4,...
Nov 25, 2020 10:15 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers – ICPT
Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc.  (“Intercept” or the “Company”) (NASDAQ: ICPT) and certain of its officers.   The class action, filed in United States District Court for the...
Nov 24, 2020 07:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Celsion, Citigroup, Raytheon, Intercept Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Celsion Corporation (NASDAQ: CLSN), Citigroup, Inc. (NYSE: C), Raytheon...
Nov 24, 2020 06:28 pm ET
ROSEN, A LEADING LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact
NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the "Class Period"), of the important January 4, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Intercept investors under the federal securities laws.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.